نتایج جستجو برای: autoimmune hemolytic anemia

تعداد نتایج: 123701  

2016
James W Swann Barbara J Skelly

© 2016 Swann and Skelly. This work is published by Dove Medical Press Limited, and licensed under a Creative Commons Attribution License. The full terms of the License are available at http://creativecommons.org/licenses/by/4.0/. The license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. © 2016 Swann and Skelly. This...

Journal: :Indian pediatrics 2015
Dhwanee Thakkar Nita Radhakrishnan P K Pruthi Anupam Sachdeva

BACKGROUND Association of autoimmune haemolytic anaemia has been seldom reported with Kawasaki disease. CASE CHARACTERISTICS A 7-month-old boy, presented with prolonged fever, erythematous rash, severe pallor and hepatosplenomegaly. OBSERVATIONS Positive Direct Coombs test and coronary artery aneurysm on echocardiography. He was managed with steroids along with intravenous immunoglobulins a...

2015
Dhrubajyoti Bandyopadhyay Adrija Hajra Sabyasachi Mukhopadhyay Vijayan Ganesan Manas layek Debarati Bhar Diptak Bhowmick Cankatika choudhury Partha Sarathi Karmakar

We report a case of hemolytic anemia as an initial manifestation of hepatitis A virus infection. On admission, the patient had anemia, reticulocytosis, and direct and indirect hyperbilirubinemia. On subsequent examination, he had both glucose-6-phosphate dehydrogenase deficiency (G6PD) and autoimmune antibodies.

2017

Hemolytic anemia is characterized by intravascular and extravascular destruction of erythrocytes. It manifests if the production of the erythrocytes in the bone marrow is slower than their degradation. A first good differentiation of the several forms of hemolytic anemia can be made between ‘hereditary’ and ‘acquired’. In this article, the most important forms of acquired hemolytic anemia are p...

2016
Amruth R. Palla Devin Kennedy Hossain Mosharraf Donald Doll

Recently, immunotherapeutic drugs, including PD-1 inhibitors (nivolumab, pembrolizumab), PD-L1 inhibitors (atezolizumab, avelumab), and CTLA4 inhibitors (ipiliumumab), have emerged as important additions to the armamentarium against certain malignancies and have been incorporated into therapeutic protocols for first-, second-, or third-line agents for these metastatic cancers. Immune checkpoint...

Journal: :Asian Journal of Transfusion Science 2013

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید